

RealRate

PHARMACEUTICAL 2021











RealRate

PHARMACEUTICAL 2021





The relative strengths and weaknesses of Kronos Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kronos Bio Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Kronos Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 208% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	419,802
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,856
Liabilities, Non-Current	33,589
Other Assets	92,162
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-30,400
Other Revenues	0
Property and Equipment	0
Research and Development	43,250
Selling, General and Administrative Expense	14,794

Output Variable	Value in 1000 USD
Assets	511,964
Liabilities	46,445
Expenses	58,044
Revenues	0
Stockholders Equity	465,519
Net Income	-88,444
Comprehensive Net Income	-88,444
Economic Capital Ratio	255%

